Acquisition History / GSK plc / RAPT Therapeutics, Inc.
GSK plc Acquires RAPT Therapeutics, Inc.
Announced January 20, 2026 — $1.90B
What happened
RAPT Therapeutics is developing ozureprubart, a potentially best-in-class anti-IgE antibody for food allergy. GSK agreed on January 20, 2026 to pay RAPT shareholders $58.00 per share at closing, an estimated upfront investment of $1.9B net of cash acquired.
- Acquirer
- GSK plc
- Target
- RAPT Therapeutics, Inc.
- Announced
- January 20, 2026
- Price
- $1.90B
- Industry
- Allergy and immunology biotechnology
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did GSK plc acquire RAPT Therapeutics, Inc.?
GSK plc acquired RAPT Therapeutics, Inc. on January 20, 2026. This was GSK plc's 1st publicly tracked acquisition out of 1 we have on record.
How much did GSK plc pay for RAPT Therapeutics, Inc.?
GSK plc paid $1.90B for RAPT Therapeutics, Inc..
What does RAPT Therapeutics, Inc. do?
RAPT Therapeutics is developing ozureprubart, a potentially best-in-class anti-IgE antibody for food allergy. GSK agreed on January 20, 2026 to pay RAPT shareholders $58.00 per share at closing, an estimated upfront investment of $1.9B net of cash acquired.
What other Allergy and immunology biotechnology companies has GSK plc acquired?
RAPT Therapeutics, Inc. is GSK plc's only publicly tracked acquisition in Allergy and immunology biotechnology so far.